

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP05/050362

International filing date: 28 January 2005 (28.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/543,107
Filing date: 09 February 2004 (09.02.2004)

Date of receipt at the International Bureau: 17 February 2005 (17.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

PCT

PCT/EP2005/050362
31.01.05

PA 1242998

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office


November 03, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/543,107

FILING DATE: February 09, 2004

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



N. Woodson
N. WOODSON
Certifying Officer

Docket Number

LS/91-23017/P1/PROV

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 80352678/US

"Express Mail" label mailing number

2/9/04

Date of Deposit

To: Mail Stop: Provisional Patent Applications
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

15535 U.S. PTO
60/543107

020904

PROVISIONAL PATENT APPLICATION COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION for patent under 37 CFR 1.53 (c).

INVENTOR(s)/APPLICANT(s)			
LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)
van der Schaaf	Paul	A.	Allschwil, Switzerland
Blatter	Fritz		Reinach, Switzerland
Szelagiewicz	Martin		Münchenstein, Switzerland
Berens	Ulrich		Binzen, Germany

TITLE OF THE INVENTION (280 characters max)

Crystalline forms of Zolmitriptan

CORRESPONDENCE ADDRESS

JoAnn Villamizar
 Ciba Specialty Chemicals Corporation
 Patent Department

Mailing Address	State	Zip Code	Country
540 White Plains Road P.O. Box 2005 Tarrytown	NEW YORK	10591-9005	U.S.A.

ENCLOSED APPLICATION PARTS (check all that apply)

☒ 27 pages of Specification
 (and any claims)

☒ 1 pages of Abstract

☒ 7 sheets of Figures

☐ Other (specify)

METHOD OF PAYMENT

The Commissioner is hereby authorized to charge filing fees and
 additional fees required to Deposit Account Number: 03-1935.

PROVISIONAL FILING FEE AMOUNT: (\$160.00)

☐ U.S. Government agency and contract number: _____ (if the invention was made by an agency of the
 United States Government or under a contract with an agency of the United States Government.)

Respectfully submitted,

Tyler A. Stevenson
 Agent for Applicants
 Reg. No. 46,388


Tel. No. (914) 785-7127
 Date: February 9, 2004

Crystalline forms of Zolmitriptan

The present invention is directed to crystalline forms of Zolmitriptan, processes for the preparation thereof and pharmaceutical compositions comprising these crystalline forms.

The present invention relates to crystalline forms of Zolmitriptan. Zolmitriptan is known by the chemical name, (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone.

Zolmitriptan has the following formula:



Zolmitriptan is a selective 5-hydroxytryptamine _{1B/1D} (5-HT_{1B/1D}) receptor agonist. Zolmitriptan is marketed as an oral formulation for acute treatment of migraine.

Processes for the preparation of Zolmitriptan are described in WO-A-91/18897, WO-A-97/06162 and WO-A-98/02186, and in the publications by J. Buckingham et al. in *Journal of Medicinal Chemistry* (1995), vol. 38, pages 3566-3580 and J. Ngo et al. in *Drugs of the Future* (1997), vol. 22, pages 260-269. The processes in the above mentioned patents and publications results either in the preparation of Zolmitriptan isopropanolate containing half a molecule of water, or a Zolmitriptan ethyl acetate solvate which is subsequently treated in an acetone/water mixture. These patents and publications do not describe the crystallinity of the products or the characterization of the solid state properties. It is known that pharmaceutical substances can exhibit polymorphism. Polymorphism is commonly defined as the ability of any substance to have two or more different crystal structures. Drug substances may also encapsulate solvent molecules when crystallized. These solvates or hydrates are referred to as pseudopolymorphs. Solvated forms may contain substantial amounts of residual solvent and are normally not practical for the manufacturing of pharmaceutical products. However, such solvates may be valuable intermediates to prepare stable, and solvent free crystal forms. It is therefore important to find appropriate processes to transform solvated forms into non-solvated forms by suitable desolvation processes. Different polymorphs,

pseudopolymorphs or the amorphous form differ in their physical properties such as melting point, solubility etc. These can appreciably influence pharmaceutical properties such as dissolution rate and bioavailability. It is therefore important to evaluate polymorphism of drug substances. Furthermore, the discovery of new crystalline polymorphic forms of a drug enlarge the repertoire of materials that a formulation scientist has with which to design a pharmaceutical dosage form of a drug with a targeted release profile or other desired characteristics. We now have surprisingly found Zolmitriptan to be polymorph and disclose a novel crystalline form of Zolmitriptan, herein designated as Form A, and several novel solvates of Zolmitriptan, herein designated as Form B, C, D, E, F, and G.

Accordingly, the present invention is directed to the polymorphic and pseudopolymorphic Forms A, B, C, D, E, F and G of Zolmitriptan and processes for preparing them.

One object of the invention is a crystalline form of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone, herein designated as Form A, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) and in 2θ as given in Table 1 (vs = very strong intensity, s = strong intensity, m = medium intensity, w = weak intensity, vw = very weak intensity).

Table 1: d-spacings and 2θ angles for Form A.

Angle °2θ	d-spacing (Å)	Qualitative Relative Intensity
9.8	9.0	vw
11.5	7.7	w
12.1	7.3	w
12.5	7.1	m
13.9	6.4	s
14.4	6.15	s
15.5	5.69	s
16.6	5.32	vw
17.4	5.10	w
18.3	4.83	vw
19.3	4.59	vs
19.6	4.53	s

20.7	4.29	w
21.1	4.22	m
22.1	4.02	s
23.1	3.85	m
24.0	3.71	vs
24.3	3.66	shoulder
25.4	3.51	w
25.8	3.45	m
27.4	3.25	m
28.1	3.17	w
29.0	3.08	s
30.6	2.92	w
31.2	2.86	m
33.0	2.71	w
34.4	2.61	w
35.8	2.50	m

Another object of the invention is a crystalline 1-butanol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone, herein designated as Form B, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) and in 2θ as given in Table 2.

Table 2: d-spacings and 2θ angles for Form B.

Angle °2θ	d-spacing (Å)	Qualitative Relative Intensity
8.3	10.7	m
8.8	10.0	w
11.3	7.9	vw
11.8	7.5	s
13.0	6.8	w
13.9	6.4	m
14.6	6.05	m
15.7	5.64	w

16.5	5.36	m
17.2	5.16	m
17.7	5.01	m
18.2	4.87	s
18.5	4.78	w
19.2	4.61	m
19.8	4.48	s
21.9	4.05	s
22.5	3.94	w
22.8	3.90	m
23.4	3.80	w
23.6	3.76	s
24.1	3.69	m
25.3	3.52	m
26.6	3.34	w
27.2	3.28	vw
27.5	3.24	w
29.4	3.03	w
29.7	3.01	w
30.5	2.93	w
31.7	2.82	w

Another object of the invention is a crystalline anisol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone, herein designated as Form C, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) and in 2θ as given in Table 3.

Table 3: d-spacings and 2θ angles for Form C.

Angle 2θ	d-spacing (Å)	Qualitative Relative Intensity
8.5	10.4	m
9.0	9.8	vw
11.4	7.8	s

12.7	7.0	vw
13.4	6.6	m
13.8	6.4	s
14.3	6.18	m
15.0	5.89	m
15.6	5.68	w
17.0	5.23	w, shoulder
17.1	5.17	m
17.7	5.00	m
18.1	4.89	s
18.3	4.84	w, shoulder
18.6	4.77	vw
20.0	4.44	vs
21.0	4.23	w
21.5	4.13	vw
22.2	4.00	s
22.7	3.92	m
23.4	3.80	m
24.0	3.70	vs
24.4	3.65	vw
25.1	3.54	m
25.7	3.46	s
26.1	3.41	m
27.6	3.23	w
28.3	3.15	w
28.9	3.09	w
30.3	2.95	w
30.6	2.92	w
31.5	2.84	vw
32.1	2.78	vw
33.3	2.69	w
33.8	2.65	w

Another object of the invention is a crystalline 2-propanol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone, herein designated as Form D, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) and in 2θ as given in Table 4.

Table 4: d-spacings and 2θ angles for Form D.

Angle °2θ	d-spacing (Å)	Qualitative Relative Intensity
8.2	10.7	s
8.8	10.0	m
11.6	7.6	vs
12.8	6.9	m
13.6	6.5	vw
14.0	6.3	s
14.6	6.1	m
15.5	5.71	w
16.5	5.38	vw
17.0	5.21	s
17.6	5.03	s
18.2	4.86	vs
18.5	4.80	shoulder
19.2	4.62	m
19.7	4.50	vs
21.6	4.11	s
21.8	4.07	m
22.8	3.90	s
23.3	3.81	m
23.7	3.75	m
24.1	3.69	s
25.3	3.52	s
25.6	3.47	vw
26.2	3.40	m
27.2	3.27	w

27.5	3.24	w
29.5	3.02	w
30.5	2.93	w
31.6	2.83	w
32.9	2.72	vw

Another object of the invention is a crystalline ethyl methyl ketone solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone, herein designated as Form E, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) and in 2θ as given in Table 5.

Table 5: d-spacings and 2θ angles for Form E.

Angle °2θ	d-spacing (Å)	Qualitative Relative Intensity
8.1	10.9	m
8.8	10.1	w
11.1	8.0	w
12.1	7.3	vs
13.7	6.5	m
14.3	6.2	s
15.8	5.60	vw
17.2	5.10	m
17.5	5.06	m
17.7	5.00	shoulder
18.3	4.85	s
18.7	4.75	m
19.0	4.66	s
19.8	4.47	vs
22.0	4.03	s
22.3	3.98	s
22.7	3.92	shoulder
23.4	3.80	m
23.9	3.72	s

24.2	3.67	m
24.4	3.64	m
25.0	3.55	s
25.7	3.46	w
26.4	3.37	w
26.9	3.31	m
29.4	3.03	w
31.0	2.88	w
31.9	2.80	w

Another object of the invention is a crystalline tetrahydrofuran solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone, herein designated as Form F, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) and in 2θ as given in Table 6.

Table 6: d-spacings and 2θ angles for Form F.

Angle °2θ	d-spacing (Å)	Qualitative Relative Intensity
8.4	10.5	m
8.8	10.0	w
11.7	7.6	s
12.9	6.8	m
13.6	6.5	vw
14.2	6.2	m
14.8	5.97	s
15.7	5.65	w
16.8	5.28	m
17.1	5.18	m
17.6	5.02	shoulder
17.8	4.98	s
18.3	4.84	s
18.6	4.78	shoulder
19.5	4.55	m

19.9	4.46	m
21.6	4.11	vs
21.9	4.05	m
22.7	3.92	vw
23.1	3.85	m
23.3	3.82	m
23.9	3.72	vs
24.3	3.66	vs
25.2	3.53	vw
25.5	3.50	m
25.8	3.45	w
26.2	3.40	m
26.7	3.34	vw
27.4	3.25	m
28.5	3.13	w
29.9	2.99	vw
31.8	2.81	w

Another object of the invention is a crystalline 1,4-dioxane solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone, herein designated as Form G, which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) and in 2θ as given in Table 7.

Table 7: d-spacings and 2θ angles for Form G.

Angle °2θ	d-spacing (Å)	Qualitative Relative Intensity
8.4	10.5	m
8.9	10.0	vw
11.4	7.8	m
12.7	7.0	w
13.4	6.6	w
13.7	6.4	w
14.3	6.2	vw
15.0	5.91	s
15.5	5.72	m

16.9	5.26	s
17.7	4.99	s
18.3	4.85	vs
19.5	4.54	m
19.8	4.47	m
21.0	4.22	m
21.8	4.08	s
22.2	4.00	w
22.7	3.92	m
22.8	3.89	m
23.2	3.82	m
24.0	3.71	m
24.4	3.65	m
25.6	3.48	m
25.9	3.43	w
27.0	3.30	w
27.5	3.24	w
28.0	3.19	vw
28.5	3.12	w
29.9	2.99	w
31.6	2.83	w
32.0	2.80	vw
32.8	2.73	w

The polymorphic Form A of Zolmitriptan is especially characterized by an X-ray powder diffraction pattern as depicted in Figure 1, whereas the Form B is especially characterized by an X-ray powder diffraction pattern as depicted in Figure 2, the Form C by an X-ray powder diffraction pattern as depicted in Figure 3, the Form D by an X-ray powder diffraction pattern as depicted in Figure 4, the Form E by an X-ray powder diffraction pattern as depicted in Figure 5, the Form F by an X-ray powder diffraction pattern as depicted in Figure 6, and the Form G by an X-ray powder diffraction pattern as depicted in Figure 7.

Furthermore, the present invention is directed to processes for the preparation of Form A, B, C, D, E, F and G of Zolmitriptan.

Form A can be generally prepared by crystallization from solutions of Zolmitriptan. Crystallization is conveniently initialized by cooling. Solutions may be formed in pure solvents or mixtures of solvents with non-solvents. For obtaining the desired form A, solutions of

Zolmitriptan must not contain a solvent or non-solvent forming solvate crystals (i.e. 1-butanol, anisole, 2-propanol, ethyl methyl ketone, tetrahydrofuran, 1,4-dioxane, ethyl acetate), such as forms B, C, D, E, F and G of Zolmitriptan, whose preparation is described further below. Examples of solvents are lower alcohols (except 2-propanol and 1-butanol), e.g. methanol, ethanol, 1-propanol, 2-butanol, tert.-butanol, or suitable sulfoxides or amides such as dimethylsulfoxide, dimethylformamide. Examples of non-solvents are alkanes or ethers, e.g. C₅-C₈alkanes and/or dialkylethers such as diethyl ether, dimethyl ether, methyl-propyl ether, tert.-butyl-methyl ether, preferably diethyl ether, dimethyl ether, tert.-butyl-methyl ether, hexane heptane. For example, form A may be obtained from cooled alcoholic solutions of Zolmitriptan. Preferably, the alcohol used is ethanol or methanol, especially ethanol, and most preferably the alcoholic solutions are mixed with water. Form A can also conveniently be prepared by crystallization from cooled solutions of Zolmitriptan in a mixture of an alcohol as mentioned above with a non-solvent. Most preferably, the alcohol is methanol or ethanol and the non-solvent is an ether. Preferably these solutions are cooled from temperatures of about 20 to 100°C down to temperatures of about -20° to 10°. Most preferably from temperatures of about 50 to 80°C down to temperatures of about 0°C to 5°C.

Form A can also be generally prepared by stirring the amorphous form in an organic solvent or non-solvent as described above. The amorphous form is generally obtained as an oil by evaporation of a solution of Zolmitriptan, e.g. an alcoholic solution of Zolmitriptan. Preferably the amorphous form is stirred in a non-solvent, e.g. an ether, most preferably in diethyl ether or methyl tert-butyl ether.

Form A can also be generally prepared by suspending Zolmitriptan in an organic solvent. These suspensions generally can be made using any crystalline form of Zolmitriptan. Preferably these suspensions are made in an alcohol or an acetate. Most preferably in 2-propanol and ethyl acetate and stirred for several hours.

Form B can be generally prepared by evaporation of a solution of Zolmitriptan in 1-butanol, or mixtures of 1-butanol with a co-solvent (e.g. an organic solvent as noted above). Preferably the cosolvent is another alcohol, and the evaporation is performed at atmospheric pressure, e.g. by treating the product with a stream of gas.

Form C can be generally prepared by stirring a suspension of Zolmitriptan in anisole.

Form D can be generally prepared by crystallization from a 2-propanol solution. Preferably by gentle evaporation of a 2-propanol solution. Most preferably the evaporation is performed by treating the product with a stream of gas, e.g. at atmospheric pressure.

Form E can be generally prepared by suspending Zolmitriptan in ethyl methyl ketone. Preferably the suspension in ethyl methyl ketone is stirred. The product may conveniently be isolated by filtration.

Form F can be generally prepared by crystallization from a tetrahydrofuran solution. Preferably by gentle evaporation of a tetrahydrofuran solution. Most preferably, the evaporation is performed by treating the product with a stream of gas, e.g. at atmospheric pressure.

Form G can be generally prepared by suspending Zolmitriptan in 1,4-dioxane. Preferably the suspension in 1,4-dioxane is stirred. The product may conveniently be isolated by filtration.

Where crystalline forms are obtained as a suspension, the product may conveniently be isolated by filtration and/or drying. The suspensions usually are treated in the temperature range 0-60°C, especially 5-30°C. Where a gas stream is used for the evaporation of solvents and/or non-solvents, the gas employed may be air or an inert gas, e.g. dried air or nitrogen.

In the above mentioned processes small amounts of seeding crystals of the desired crystalline form may be added to the reaction mixture. Preferably small amounts are about 1 to 20 weight%, more preferably about 5 weight%. Seeding crystals may be added before or, where appropriate, after the step initiating the crystallization (e.g. cooling, addition of non-solvent, evaporation etc. as described above). Addition before initiating the crystallization is of specific technical interest.

Another object of the present invention are pharmaceutical compositions comprising an effective amount of crystalline Form A, B, C, D, E, F or G of Zolmitriptan, and a pharmaceutically acceptable carrier.

These polymorphic forms may be used as single component or as mixtures with other crystalline forms or the amorphous form of Zolmitriptan.

As to Zolmitriptan it is preferred that it contains 25-100% by weight, especially 50-100% by weight of the novel form, based on the total amount of Zolmitriptan. Preferably, such an amount of the novel polymorphic form of Zolmitriptan is 75-100% by weight, especially 90-100% by weight. Highly preferred is an amount of 95-100% by weight.

The compositions of the present invention include powders, granulates, aggregates and other solid compositions comprising the novel polymorphic form of Zolmitriptan. In addition, the compositions that are contemplated by the present invention may further include diluents, such as cellulose-derived materials like powdered cellulose, microcrystalline cellulose, microfine cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose salts and other substituted and unsubstituted celluloses; starch; pregelatinized starch; inorganic diluents like calcium carbonate and calcium diphosphate and other diluents known to the pharmaceutical industry. Yet other suitable diluents include waxes, sugars and sugar alcohols like mannitol and sorbitol, acrylate polymers and copolymers, as well as pectin, dextrin and gelatin.

Further excipients that are within the contemplation of the present invention include binders, such as acacia gum, pregelatinized starch, sodium alginate, glucose and other binders used in wet and dry granulation and direct compression tableting processes. Excipients that also may be present in the solid compositions further include disintegrants like sodium starch glycolate, crospovidone, low-substituted hydroxypropyl cellulose and others. In addition, excipients may include tableting lubricants like magnesium and calcium stearate and sodium stearyl fumarate; flavorings; sweeteners; preservatives; pharmaceutically acceptable dyes and glidants such as silicon dioxide.

The dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant and ophthalmic administration. Although the most suitable route in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral. The dosages may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.

Dosage forms include solid dosage forms, like tablets, powders, capsules, suppositories, sachets, troches and lozenges as well as liquid suspensions and elixirs. While the description is not intended to be limiting, the invention is also not intended to pertain to true solutions of Zolmitriptan whereupon the properties that distinguish the solid form of Zolmitriptan are lost. However, the use of the novel form to prepare such solutions is considered to be within the contemplation of the invention.

Capsule dosages, of course, will contain the solid composition within a capsule which may be made of gelatin or other conventional encapsulating material. Tablets and powders may be coated. Tablets and powders may be coated with an enteric coating. The enteric coated powder forms may have coatings comprising phthalic acid cellulose acetate, hydroxypropylmethyl-cellulose phthalate, polyvinyl alcohol phthalate, carboxymethylethylcellulose, a copolymer of styrene and maleic acid, a copolymer of methacrylic acid and methyl methacrylate, and like materials, and if desired, they may be employed with suitable plasticizers and/or extending agents. A coated tablet may have a coating on the surface of the tablet or may be a tablet comprising a powder or granules with an enteric coating.

Preferred unit dosages of the pharmaceutical compositions of this invention typically contain from 1 to 50 mg of the novel Zolmitriptan forms or mixtures thereof with each other or other forms of Zolmitriptan. More usually, the combined weight of the Zolmitriptan forms of a unit dosage are from 0.5 mg to 30 mg, for example 1, 2.5 or 5 mg.

The following Examples illustrate the invention in more detail. Temperatures are given in degrees Celsius. If not stated otherwise, ambient atmosphere or room temperature (RT) is in the range 20-25°C. Whereever mentioned, atmospheric pressure stands for a pressure of about 10^5 Pa (e.g. 0.5 – about 1.5 bar, especially about 0.9 – about 1.1 bar, under conditions commonly used in laboratory or industrial synthesis). Abbreviations and symbols used in the Examples and elsewhere:

TBME: tert.-butyl-methyl ether
1 Å stands for 10^{-10} m.

Example 1: Preparation of Form A

83 mg of Zolmitriptan were dissolved in a mixture of 1 ml ethanol and 1 ml water at 60°C. Then slowly 4 ml of water were added after which the slightly turbid solution was cooled to 5°C at a cooling rate of about 1°C per minute. The formed suspension was stirred at this temperature for 16 hours and the solid was isolated by filtration and dried at 40°C for 2 hours. The obtained crystal Form A is characterized by an X-ray powder diffraction pattern as shown in Figure 1.

Example 2: Preparation of Form A

81 mg of Zolmitriptan were dissolved in 0.3 ml methanol. Then slowly 3 ml of methyl tert-butyl ether were added after which the slightly turbid solution was cooled to 5°C. The formed suspension was stirred at this temperature for 16 hours and the solid was isolated by filtration and dried at 40°C for 2 hours. The obtained crystal Form A is characterized by an X-ray powder diffraction pattern as shown in Figure 1.

Example 3: Preparation of Form A

101 mg of Zolmitriptan were dissolved in 1 ml 2-propanol at 60°C. This solution was cooled to 5°C at a cooling rate of about 1°C per minute. The formed suspension was stirred at this temperature for 16 hours and the solid was isolated by filtration and dried at 40°C for 2 hours. The obtained crystal Form A is characterized by an X-ray powder diffraction pattern as shown in Figure 1.

Example 4: Preparation of Form A

180 mg of Zolmitriptan were dissolved in 1 ml methanol. This solution was evaporated to dryness in vacuum giving the amorphous Zolmitriptan as an oil. This amorphous material was suspended in 2 ml methyl tert-butyl ether and stirred at room temperature for 4 hours. The crystalline solid was isolated by filtration and dried. The obtained crystal Form A is characterized by an X-ray powder diffraction pattern as shown in Figure 1.

Example 5: Preparation of Form A

110 mg Zolmitriptan was suspended in 1 ml 2-propanol and this suspension was stirred at room temperature for 16 hours. The crystalline solid was isolated by filtration and dried at room temperature. The obtained crystal Form A is characterized by an X-ray powder diffraction pattern as shown in Figure 1.

Example 6: Preparation of Form A

105 mg Zolmitriptan was suspended in 2 ml ethyl acetate and this suspension was stirred at room temperature for 40 hours. The crystalline solid was isolated by filtration and dried at room temperature. The obtained crystal Form A is characterized by an X-ray powder diffraction pattern as shown in Figure 1.

Example 7: Preparation of Form B

70 mg Zolmitriptan was dissolved in a mixture of 1 ml 1-butanol and 1 ml water free ethanol. This solution was evaporated to dryness under a weak flow of dry nitrogen over a period of 16 hours. The obtained crystal Form B is characterized by an X-ray powder diffraction pattern as shown in Figure 2. A TG-FTIR analysis showed that the product contains about 10% 1-butanol.

Example 8: Preparation of Form B

49 mg Zolmitriptan was dissolved in 2 ml 1-butanol at room temperature. This solution was evaporated to dryness under a weak flow of dry nitrogen. The obtained crystal Form B is characterized by an X-ray powder diffraction pattern as shown in Figure 2. A TG-FTIR analysis showed that the product contains about 16% 1-butanol.

Example 9: Preparation of Form C

72 mg Zolmitriptan were suspended in 1 ml anisole, and this suspension was stirred at room temperature for 18 hours. The crystalline solid was isolated by filtration and dried at room temperature. The obtained crystal Form C is characterized by an X-ray powder diffraction pattern as shown in Figure 3. A TG-FTIR analysis showed that the product contains about 23% anisole.

Example 10: Preparation of Form D

110 mg Zolmitriptan were dissolved in 4 ml 2-propanol at 60°C. After cooling the solution to room temperature the solvent is evaporated using a stream of dry nitrogen gas. The obtained crystalline Form D is characterized by an X-ray powder diffraction pattern as shown in Figure 4. A TG-FTIR analysis showed that the product contains about 13% 2-propanol.

Example 11: Preparation of Form E

75 mg Zolmitriptan are suspended in 1 ml ethyl methyl ketone, and stirred at room temperature for 16 hours. The crystalline solid was isolated by filtration and dried at room temperature. The obtained crystal Form E is characterized by an X-ray powder diffraction pattern as shown in Figure 5. A TG-FTIR analysis showed that the product contains about 11% ethyl methyl ketone.

Example 12: Preparation of Form F

50 mg Zolmitriptan are dissolved in 2 ml tetrahydrofuran. This solution was evaporated to dryness using a stream of dry nitrogen gas. The obtained crystal Form F is characterized by an X-ray powder diffraction pattern as shown in Figure 6. A TG-FTIR analysis showed that the product contains about 17% tetrahydrofuran.

Example 13: Preparation of Form G

79 mg Zolmitriptan are suspended in 1 ml 1,4-dioxane, and stirred at room temperature for about 16 hours. The crystalline solid was isolated by filtration and dried at room temperature. The obtained crystal Form G is characterized by an X-ray powder diffraction pattern as shown in Figure 7. A TG-FTIR analysis showed that the product contains about 21% 1,4-dioxane.

Powder X-ray diffraction analysis

PXRD was performed on a Philips 1710 powder X-ray diffractometer using $\text{Cu}_{K\alpha}$ radiation. D-spacings were calculated from the 2θ using the wavelength of the $\text{Cu}_{K\alpha 1}$ radiation of 1.54060 Å. The X-ray tube was operated at a Voltage of 45kV, and a current of 45 mA. A step size of 0.02° , and a counting time of 2.4 s per step was applied. Generally, 2θ values are within an error of ± 0.1 - 0.2° . The experimental error on the d-spacing values is therefore dependent on the peak location.

Brief description of the drawing

Figure 1 is a characteristic X-ray powder diffraction pattern for Form A
Figure 2 is a characteristic X-ray powder diffraction pattern for Form B
Figure 3 is a characteristic X-ray powder diffraction pattern for Form C
Figure 4 is a characteristic X-ray powder diffraction pattern for Form D
Figure 5 is a characteristic X-ray powder diffraction pattern for Form E
Figure 6 is a characteristic X-ray powder diffraction pattern for Form F

Figure 7 is a characteristic X-ray powder diffraction pattern for Form G

Claims

1. A crystalline polymorph A of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 6.4 (s), 6.15 (s), 5.69 (s), 4.59 (vs), 4.53 (s), 4.02 (s), 3.71 (vs), 3.08 (s); wherein (vs) = very strong intensity; (s) = strong intensity.
2. A crystalline polymorph A of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 7.1 (m), 6.4 (s), 6.15 (s), 5.69 (s), 4.59 (vs), 4.53 (s), 4.22 (m), 4.02 (s), 3.85 (m), 3.71 (vs), 3.45 (m), 3.25 (m), 3.08 (s), 2.86 (m), 2.50 (m); wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity.
3. A crystalline polymorph A of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 7.7 (w), 7.38 (w), 7.1 (m), 6.4 (s), 6.15 (s), 5.69 (s), 5.10 (w), 4.59 (vs), 4.53 (s), 4.29 (w), 4.22 (m), 4.02 (s), 3.85 (m), 3.71 (vs), 3.51 (w), 3.17 (w), 3.45 (m), 3.25 (m), 3.08 (s), 2.92 (w), 2.86 (m), 2.71 (w), 2.61 (w), 2.50 (m); wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity.
4. A crystalline polymorph A of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone having an X-ray powder diffraction pattern substantially as depicted in figure 1.
5. A crystalline 1-butanol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 7.5 (s), 4.87 (s), 4.48 (s), 4.05 (s), 3.76 (s); wherein (s) = strong intensity.
6. A crystalline 1-butanol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 10.7 (m), 7.5 (s), 6.4 (m), 6.05 (m), 5.36

(m), 5.16 (m), 5.01 (m), 4.87 (s), 4.61 (m), 4.48 (s), 4.05 (s), 3.90 (m), 3.76 (s), 3.69 (m), 3.52 (m); wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity.

7. A crystalline 1-butanol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 10.7 (m), 10.0 (w), 7.5 (s), 6.8 (w), 6.4 (m), 6.05 (m), 5.64 (w), 5.36 (m), 5.16 (m), 5.01 (m), 4.87 (s), 4.78 (w), 4.61 (m), 4.48 (s), 4.05 (s), 3.94 (w), 3.90 (m), 3.80 (w), 3.76 (s), 3.69 (m), 3.52 (m), 3.34 (w), 3.24 (w), 3.03 (w), 3.01 (w), 2.93 (w), 2.82 (w); wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity.
8. A crystalline 1-butanol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone having an X-ray powder diffraction pattern substantially as depicted in figure 2.
9. A crystalline 1-butanol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claims 5 to 8 containing up to 20% of 1-butanol.
10. A crystalline anisol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 7.8 (s), 6.4 (s), 4.89 (s), 4.44 (vs), 4.00 (s), 3.70 (vs), 3.46 (s); wherein (vs) = very strong intensity; (s) = strong intensity.
11. A crystalline anisol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 10.4 (m), 7.8 (s), 6.6 (m), 6.4 (s), 6.18 (m), 5.89 (m), 5.17 (m), 5.00 (m), 4.89 (s), 4.44 (vs), 4.00 (s), 3.92 (m), 3.80 (m), 3.70 (vs), 3.54 (m), 3.46 (s), 3.41 (m); wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity.
12. A crystalline anisol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 10.4 (m), 7.8 (s), 6.6 (m), 6.4 (s), 6.18

(m), 5.89 (m), 5.68 (w), 5.23 (w, shoulder), 5.17 (m), 5.00 (m), 4.89 (s), 4.84 (w, shoulder), 4.44 (vs), 4.23 (w), 4.00 (s), 3.92 (m), 3.80 (m), 3.70 (vs), 3.54 (m), 3.46 (s), 3.41 (m), 3.23 (w), 3.15 (w), 3.09 (w), 2.95 (w), 2.92 (w), 2.69 (w), 2.65 (w); wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity.

13. A crystalline anisol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone having an X-ray powder diffraction pattern substantially as depicted in figure 3.
14. A crystalline anisol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claims 10 to 13 containing up to 25% anisole.
15. A crystalline isopropanol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 10.7 (s), 7.6 (vs), 6.3 (s), 5.21 (s), 5.03 (s), 4.86 (vs), 4.50 (vs), 4.11 (s), 3.90 (s), 3.69 (s), 3.52 (s); wherein (vs) = very strong intensity; (s) = strong intensity.
16. A crystalline isopropanol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 10.7 (s), 10.0 (m), 7.6 (vs), 6.9 (m), 6.3 (s), 6.1 (m), 5.21 (s), 5.03 (s), 4.86 (vs), 4.62 (m), 4.50 (vs), 4.11 (s), 4.07 (m), 3.90 (s), 3.81 (m), 3.75 (m), 3.69 (s), 3.52 (s), 3.40 (m); wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity.
17. A crystalline isopropanol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 10.7 (s), 10.0 (m), 7.6 (vs), 6.9 (m), 6.3 (s), 6.1 (m), 5.71 (w), 5.21 (s), 5.03 (s), 4.86 (vs), 4.62 (m), 4.50 (vs), 4.11 (s), 4.07 (m), 3.90 (s), 3.81 (m), 3.75 (m), 3.69 (s), 3.52 (s), 3.40 (m), 3.27 (w), 3.24 (w), 3.02 (w), 2.93 (w), 2.83 (w); wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity.

18. A crystalline isopropanol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone having an X-ray powder diffraction pattern substantially as depicted in figure 4.
19. A crystalline isopropanol solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claims 15 to 18 containing up to 20% isopropanol.
20. A crystalline ethyl methyl ketone solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 7.3 (vs), 6.2 (s), 4.85 (s), 4.66 (s), 4.47 (vs), 4.03 (s), 3.98 (s), 3.72 (s), 3.55 (s); wherein (vs) = very strong intensity; (s) = strong intensity.
21. A crystalline ethyl methyl ketone solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 10.9 (m), 7.3 (vs), 6.5 (m), 6.2 (s), 5.10 (m), 5.06 (m), 4.85 (s), 4.75 (m), 4.66 (s), 4.47 (vs), 4.03 (s), 3.98 (s), 3.80 (m), 3.72 (s), 3.67 (m), 3.64 (m), 3.55 (s), 3.31 (m); wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity.
22. A crystalline ethyl methyl ketone solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 10.9 (m), 10.1 (w), 8.0 (w), 7.3 (vs), 6.5 (m), 6.2 (s), 5.10 (m), 5.06 (m), 4.85 (s), 4.75 (m), 4.66 (s), 4.47 (vs), 4.03 (s), 3.98 (s), 3.80 (m), 3.72 (s), 3.67 (m), 3.64 (m), 3.55 (s), 3.46 (w), 3.37 (w), 3.31 (m), 3.03 (w), 2.88 (w), 2.80 (w); wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity.
23. A crystalline ethyl methyl ketone solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone having an X-ray powder diffraction pattern substantially as depicted in figure 5.

24. A crystalline ethyl methyl ketone solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claims 20 to 23 containing up to 15% ethyl methyl ketone.
25. A crystalline tetrahydrofuran solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 7.6 (s), 5.97 (s), 4.98 (s), 4.84 (s), 4.11 (vs), 3.72 (vs), 3.66 (vs); wherein (vs) = very strong intensity; (s) = strong intensity.
26. A crystalline tetrahydrofuran solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 10.5 (m), 7.6 (s), 6.8 (m), 6.2 (m), 5.97 (s), 5.28 (m), 5.18 (m), 4.98 (s), 4.84 (s), 4.55 (m), 4.46 (m), 4.11 (vs), 4.05 (m), 3.85 (m), 3.82 (m), 3.72 (vs), 3.66 (vs), 3.50 (m), 3.40 (m), 3.25 (m); wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity.
27. A crystalline tetrahydrofuran solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 10.5 (m), 10.0 (w), 7.6 (s), 6.8 (m), 6.2 (m), 5.97 (s), 5.65 (w), 5.28 (m), 5.18 (m), 4.98 (s), 4.84 (s), 4.55 (m), 4.46 (m), 4.11 (vs), 4.05 (m), 3.85 (m), 3.82 (m), 3.72 (vs), 3.66 (vs), 3.50 (m), 3.45 (w), 3.40 (m), 3.25 (m), 3.13 (w), 2.81 (w); wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity.
28. A crystalline tetrahydrofuran solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone having an X-ray powder diffraction pattern substantially as depicted in figure 6.
29. A crystalline tetrahydrofuran solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claims 25 to 28 containing up to 25% tetrahydrofuran.
30. A crystalline 1,4-dioxane solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern

with characteristic peaks expressed in d-values (Å) at 5.91 (s), 5.26 (s), 4.99 (s), 4.85 (vs), 4.08 (s); wherein (vs) = very strong intensity; (s) = strong intensity.

31. A crystalline 1,4-dioxane solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 10.5 (m), 7.8 (m), 5.91 (s), 5.72 (m), 5.26 (s), 4.99 (s), 4.85 (vs), 4.54 (m), 4.47 (m), 4.22 (m), 4.08 (s), 3.92 (m), 3.89 (m), 3.82 (m), 3.71 (m), 3.65 (m), 3.48 (m); wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity.
32. A crystalline 1,4-dioxane solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at 10.5 (m), 7.8 (m), 7.0 (w), 6.6 (w), 6.4 (w), 5.91 (s), 5.72 (m), 5.26 (s), 4.99 (s), 4.85 (vs), 4.54 (m), 4.47 (m), 4.22 (m), 4.08 (s), 4.00 (w), 3.92 (m), 3.89 (m), 3.82 (m), 3.71 (m), 3.65 (m), 3.48 (m), 3.43 (w), 3.30 (w), 3.24 (w), 3.12 (w), 2.99 (w), 2.83 (w), 2.73 (w); wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity.
33. A crystalline 1,4-dioxane solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone having an X-ray powder diffraction pattern substantially as depicted in figure 7.
34. A crystalline 1,4-dioxane solvate of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claims 30 to 33 containing up to 25% of 1,4-dioxane.
35. Process for the manufacture of crystalline polymorph A of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claims 1-4 wherein a solution of Zolmitriptan in an organic solvent or mixture of organic solvents is cooled, provided that the solution does not contain 1-butanol, anisole, 2-propanol, ethyl methyl ketone, tetrahydrofuran, 1,4-dioxane, ethyl acetate.
36. Process of claim 35, wherein an organic solvent is selected from C₁-C₄alkanois, sulfoxides and/or amides.

37. Process of claim 35, wherein the organic solvent is selected from methanol and ethanol, and the solution additionally contains water.
38. Process of claim 35, wherein the solution additionally contains a non-solvent selected from alkanes and ethers.
39. Process according to claim 35 in which the solution is cooled from a temperature of about 20° to 100°C down to about -20°C to 0°C.
40. Process for the manufacture of crystalline polymorph A of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claims 1-4 wherein the amorphous form of Zolmitriptan is stirred in an organic solvent or non-solvent.
41. Process of claim 40, wherein the amorphous form is obtained from a solution of Zolmitriptan in an organic solvent by evaporation of the organic solvent.
42. Process of claim 40, wherein the amorphous form is stirred in a non-solvent.
43. Process for the manufacture of crystalline polymorph A of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claims 1-4 wherein crystalline Zolmitriptan is suspended in an organic solvent.
44. Process of claim 43, wherein the organic solvent is an alcohol or an acetate.
45. Process for the manufacture of crystalline polymorph B of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claims 5-9, where in a solution of Zolmitriptan in 1-butanol or mixture of 1-butanol and another organic solvent, the 1-butanol or mixture of 1-butanol and organic solvent is evaporated.
46. Process of claim 45, wherein 1-butanol is the only solvent or wherein methanol and/or ethanol is the other organic solvent.

47. Process for the manufacture of crystalline polymorph C of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claims 10-14, wherein a suspension of Zolmitriptan is stirred in anisole.
48. Process for the manufacture of crystalline polymorph D of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claims 15-19, wherein a solution of Zolmitriptan in 2-propanol is cooled and/or the 2-propanol is evaporated.
49. Process for the manufacture of crystalline polymorph E of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claims 20-24, wherein a suspension of Zolmitriptan is stirred in ethyl methyl ketone.
50. Process for the manufacture of crystalline polymorph F of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claims 25-29, wherein a solution of Zolmitriptan in tetrahydrofuran is cooled and/or the tetrahydrofuran is evaporated.
51. Process for the manufacture of crystalline polymorph G of (S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone according to claims 30-34, wherein Zolmitriptan is suspended in 1,4-dioxane.
52. A process according to any of the claims 35 to 51, wherein seeding is carried out with crystals of the desired crystalline polymorph.
52. A process according to any of the claims 35 to 52 in which the solution of Zolmitriptan is prepared in situ.
53. A process according to claim 52 in which Zolmitriptan is prepared by a Fischer-indolization reaction.
54. A pharmaceutical composition comprising a crystalline polymorphic form according to any of claims 1 to 34, and a pharmaceutically acceptable carrier.

55. Zolmitriptan containing a crystalline polymorphic form according to any of claims 1 to 34.

Abstract

The present invention is directed to a novel crystalline form of Zolmitriptan, herein designated as Form A, and several novel solvates of Zolmitriptan, herein designated as Form B, C, D, E, F, and G, processes for the preparation thereof and pharmaceutical compositions comprising these crystalline forms.

Figure 1:




Figure 2:




Figure 3:




Figure 4:




Figure 5:




Figure 6:




Figure 7:

